⌕
Dr. Reddy's Laboratories · RDY · NYSE
Tenet 45 · Mixed
Compare
$14.79+0.61%At closeTenet 45 · Mixed
$14.79+0.09 (+0.61%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD

Dr. Reddy's Laboratories (RDY) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

11 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 98% below its peak, net margin 12.6%; free cash flow runs at 44% of net income. Check the accrual gap.
The lines that matter · FY22–FY26
Revenue ($M)—
3,580.0
FY22→FY26CAGR −64.1%/yr
Net income ($M)—
452.0
FY22→FY26CAGR −62.8%/yr
Free cash flow ($M)—
197.0
FY22→FY26CAGR −61.6%/yr
What the receipts whisper · what a headline number hides
Share count
+0.3%

832.1mn → 834.7mn diluted shares since FY22. Broadly flat, so EPS moves with net income rather than with the share count.

What the income statement says · FY22–FY26
Where every revenue dollar goes · FY26 ($M)3580.0Revenue−1691.0COGS1889.0Gross profit−256.0R&D−1137.0SG&A539.0Op income−87.0Tax & other452.0Net income

13¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.

Margin trend · direction beats level Gross Operating Net
604530150%sector median net margin ~3%FY22FY26

Over this window: gross 53.1% → 52.8%. Net margin 12.6% is more than double the sector median.

The receipt · income statement · FY22–FY26 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemFY26 †FY26FY25FY24FY23FY22YoYCAGR 22→26
Revenue & profitability
Revenue
3,580.03,580.00.00.00.0214,391.0—−64.1%
Cost of revenue
1,691.01,691.00.00.00.0100,551.0—−64.0%
Gross profit
1,889.01,889.0—A—A—A113,840.0——
Research & development
256.0256.00.00.00.017,482.0—−65.2%
Selling, general & admin
1,137.01,137.00.00.00.062,081.0—−63.2%
Total operating expenses
1,350.01,350.00.00.00.084,364.0—−64.4%
Operating incomefeeds ROC rank
539.0539.00.00.00.029,476.0—−63.2%
Other income, net
45.045.00.00.00.02,822.0——
Pretax income
584.0584.00.00.00.032,298.0—−63.3%
Income tax
132.0132.00.00.00.08,730.0—−64.9%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
452.0452.00.00.00.023,568.0—−62.8%
Per share
Diluted EPSbuyback-sensitive
——B—B—B—B—B——
Diluted shares (mn)
834.66834.66834.46834.09832.64832.13▲0.0%+0.1%
Margins
Gross margin31st pct in Healthcare
52.8%52.8%—A—A—A53.1%——
Operating margin
15.1%15.1%———13.7%——
Net margin73rd pct in Healthcare
12.6%12.6%———11.0%——
† FY26 = fiscal 2026, through 2026-03-31; the trailing year is not available.A Withheld: cost of revenue is not on file, so the gross margin is not measured.B Withheld by our checks.
FY16 – FY21 · 6 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 6 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-05-29 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Dr. Reddy's Laboratories' net income?

Dr. Reddy's Laboratories reported net income of $452.0M in fiscal 2026, a net margin of 12.6%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.